menu
    • menu
    [{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"OLX301A","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Laboratoires Thea \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"4","companyTruncated":"Laboratoires Thea \/ Laboratoires Th\u00e9a"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Ripple Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Laboratoires Thea \/ Th\u00e9a Open Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Th\u00e9a Open Innovation"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Ripple Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"Laboratoires Thea \/ Th\u00e9a Open Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Th\u00e9a Open Innovation"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Nevakar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Laboratoires Thea \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Laboratoires Th\u00e9a"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Coave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CTx-PDE6b","moa":"PDE6B gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Laboratoires Thea","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravitreal","sponsorNew":"Laboratoires Thea \/ Th\u00e9a","highestDevelopmentStatusID":"7","companyTruncated":"Laboratoires Thea \/ Th\u00e9a"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Akorn Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Laboratoires Thea \/ Th\u00e9a","highestDevelopmentStatusID":"12","companyTruncated":"Laboratoires Thea \/ Th\u00e9a"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Vyluma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Atropine","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Solution\/Drops","sponsorNew":"Laboratoires Thea \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Laboratoires Th\u00e9a"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Vyluma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atropine","moa":"ACh receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Laboratoires Thea \/ Laboratories Thea","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Laboratories Thea"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Prasco Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Thea Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharma \/ Thea Pharma"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"ProQR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Laboratoires Thea","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.19,"dosageForm":"Injectable\/Injection","sponsorNew":"Laboratoires Thea \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"Laboratoires Thea \/ Laboratoires Thea"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"ProQR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Laboratoires Thea","amount2":0.19,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Laboratoires Thea \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"Laboratoires Thea \/ Laboratoires Thea"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Laboratoires Thea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Laboratoires Thea

    Menu

    Laboratoires Thea

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Recipient : ProQR Therapeutics

                            Deal Size : $186.3 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic A...

                            Details : The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.

                            Brand Name : QR-110

                            Molecule Type : Large molecule

                            Upfront Cash : $8.6 million

                            December 08, 2023

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Recipient : ProQR Therapeutics

                            Deal Size : $186.3 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bimatoprost by Laboratoires Thea for Open-Angle Glaucoma: Likelihood of Approval

                            Details : T-4032 (bimatoprost) is under development for the treatment of open-angle glaucoma and ocular hypertension. It is administered by ophthalmic route as drops. It acts by targeting prostaglandin F2 alpha.

                            Brand Name : T4032

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

                            Details : Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).

                            Brand Name : Iyuzeh

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Recipient : ProQR Therapeutics

                            Deal Size : $162.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ult...

                            Details : The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.

                            Brand Name : QR-110

                            Molecule Type : Large molecule

                            Upfront Cash : $13.7 million

                            August 01, 2023

                            Lead Product(s) : Sepofarsen

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Recipient : ProQR Therapeutics

                            Deal Size : $162.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IYUZEH™ (Latanoprost Ophthalmic Solution) 0.005%, The First and Only Preservative-Free Latanoprost Ophthalmi...

                            Details : Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).

                            Brand Name : Iyuzeh

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2023

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Thea Pharma Announces FDA Approval of IYUZEH™ for the Reduction of Elevated Intraocular Pressure (IOP) in Pa...

                            Details : IYUZEH™ is the first and only clinically proven formulation of latanoprost available in the United States that is preservative-free. IYUZEH™ is formulated without any of the preservatives commonly used in topical ocular preparations, including benzal...

                            Brand Name : Iyuzeh

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2022

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Thea Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafluprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Prasco Laboratories

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution

                            Details : Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

                            Brand Name : Tafluprost-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 18, 2022

                            Lead Product(s) : Tafluprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Prasco Laboratories

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Vyluma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in ...

                            Details : NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.

                            Brand Name : NVK-002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 27, 2022

                            Lead Product(s) : Atropine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Vyluma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Vyluma

                            Deal Size : $150.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vyluma and Laboratoires Thea Enter into Licensing Agreement for the Registration and Commercialization of NVK0...

                            Details : The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.

                            Brand Name : NVK002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 14, 2022

                            Lead Product(s) : Atropine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Vyluma

                            Deal Size : $150.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed

                            Laboratoires Thea

                            France arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafluprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Akorn Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Théa to Acquire Branded Ophthalmic Products from Akorn, Expanding Théa’s Presence into the U.S. Eye Care I...

                            Details : The purchase will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan®, to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growt...

                            Brand Name : Zioptan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 28, 2022

                            Lead Product(s) : Tafluprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Akorn Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth